Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

AstraZeneca Plc’s Chief Executive Officer ... including data from its experimental cholesterol drug that significantly reduced “bad” cholesterol in a mid-stage trial. That could be part ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Australian study finds no adverse impact of repeated Covid vaccinations on metabolism, inflammation, or cardiovascular ...

(NewsNation) — AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage ...

They have a cholesterol level above 70 ... is it fair to say that under all contemplated scenarios and in light of AstraZeneca's actions over the next two to three years, tariffs are not material ...

An investigational drug, currently known as AZD0780, lowers low-density-lipoprotein cholesterol (LDL-C ... The trial was funded by AstraZeneca, the manufacturer of AZD0780. The four daily doses ...